Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

Last updated: July 23, 2019
Sponsor: Assiut University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lupus

Treatment

N/A

Clinical Study ID

NCT04022421
17300279
  • Ages > 18
  • All Genders

Study Summary

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All patients diagnosed with Behcet's disease on any DMARDs

Exclusion

Exclusion Criteria:

  • Patients with critical conditions

  • Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.

Study Design

Total Participants: 50
Study Start date:
October 01, 2018
Estimated Completion Date:
October 31, 2019

Connect with a study center

  • Assiut University Hospital

    Assiut,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.